Pipeline

BEAM Alliance

The pipeline of antimicrobial products under development is thin. But innovative.

Indeed, the antimicrobial products under development display a variety of pharmacological effects and applications.

They are described in the BEAM Infection Curve (BIC); read the memo to find out more.

Take a look at all these products that could save lives in the future.

BEAM Alliance

Pipeline RX

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
Telum TherapeuticsEpleTTX43aProtein/PeptideEnterococcus faecium (VRE) - Broad Gram-positive infectionsDiscovery
Telum TherapeuticsEpleTTX33aProtein/PeptideStaphylococcus aureus (MRSA)- Respiratory infectionsLead opt
Telum TherapeuticsEpleTTX23aProtein/PeptidePseudomonas aeruginosa (MDR) - Respiratory infectionsPre-clinical
Telum TherapeuticsEpleTTX13aProtein/PeptideAcinetobacter baumannii (CRA) - HABP/VABP (Gram-negative)Pre-clinical
Ilya PharmaILP101-InhaleOtherMDR bacteria in the mucus layer of lung/upper respiratory tract infections. Restoring lung function in or following ARDS.Pre-clinical
Ilya PharmaILP100-OralOtherTreating colitis, improving mucosal healing, limiting risk of sepsis with MDR bacteria, increasing number of patients that can stay on ICIs, improving PFSIND/CTA ready
Ilya PharmaILP100-TopicalOtherHealing skin wounds in pediatric patients with interferonophaties like SAVI (STING Associated Vasculophaty with onset in infancy)Phase III
Basilea Pharmaceutica InternationalBAL2062 3aNMEInvasive aspergillosis Phase I
Basilea Pharmaceutica InternationalFosmanogepix3aNMEInvasive mold infections (including invasive aspergillosis, fusariosis, Scedoporium and Lomentospora, mucormycosis and other rare mold infections)Phase II
Basilea Pharmaceutica InternationalFosmanogepix3aNMECandidemia / invasive candidiasis (including Candida auris)Phase III
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEAspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis),  mucormycosis and cryptococcosisMarketed
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEInvasive aspergillosis and mucormycosis Marketed
Eligo BioscienceEB0034aPhageHemolytic uremic syndrome (HUS)IND/CTA ready
OM PharmaUro-Vaxom®1aOtherRecurrent lower urinary tract infections (i.e. cystitis)Marketed
OM PharmaBroncho-Vaxom® (Bacterial Lysates – OM-85)1aOtherRecurrent Respiratory Tract Infections (RTIs)Marketed
OM PharmaOM-851aOtherRespiratory Tract Infections (RTIs)Phase II
OM PharmaOM-891aOtherCommunity acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Phase I
OM PharmaOM-851aOtherUncomplicated urinary tract infections (uUTI)Phase I
DevsHealthMulti-resistant s. aureus novel treatmentNMES. aureus (methicillin resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
ArrePathAP-0013aNMEE. coli, K. pneumoniae, Enterobacter spp., Citrobacter spp., Other Enterobacterales, Salmonella spp., Shigella spp., E. faecium, N. gonorrhoeae, H. influenzae / Complicated urinary tract infections (cUTI)Lead opt
Tabrixanti-virulence agents3aNMEMycobacterium tuberculosis / Cystic fibrosis associated infectionsIND/CTA ready
GranulyticsUndisclosed3aProtein/PeptideE. coli, S. aureusPre-clinical
Santero TherapeuticsSAN-Sa13aNMES. aureusPre-clinical
UltupharmaULT13aNMEE. faecium, S. aureus, S. pneumoniae, Group A Streptococci / Complicated urinary tract infections (cUTI)IND/CTA ready
UltupharmaULT2C3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., S. aureus, S. pneumoniae, H. influenzae, Group A Streptococci /Skin and Skin-structure infections (ABSSSI)IND/CTA ready
UltupharmaULT2B3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT2A3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., S. aureus, H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT33aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Other Enterobacterales, P. aeruginosa / Skin and Skin-structure infections (ABSSSI)IND/CTA ready
VAXDYNAcinetoVax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNEcoVax1aVaccineA. baumannii, E. coli / Bloodstream infectionsPre-clinical
VAXDYNP-Vax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNK-Vax1aVaccineA. baumannii, K. pneumoniae / Bloodstream infectionsIND/CTA ready
Arivin therapeuticsViri-24253aNMEK. pneumoniae, P. aeruginosa / Chronic open woundsPre-clinical
Arivin therapeuticsViri-013aNMEK. pneumoniae, P. aeruginosa / Cystic fibrosis associated infectionsPre-clinical
Thioredoxin SystemsEbsArgent3aNMEA. baumannii, P. aeruginosa, S. aureus / Complicated urinary tract infections (cUTI)IND/CTA ready
BioNTech R&DBNT3313aProtein/PeptideBacterial VaginosisIND/CTA ready
Basilea Pharmaceutica InternationalTonabacase 3aNMESevere staphylococcal infections Phase I
Basilea Pharmaceutica InternationalBAL2420 (LptA inhibitor)3aNMESevere Enterobacteriaceae infections Pre-clinical
Nexbiome TherapeuticsBGA-19013aAntibodyH. piloriPre-clinical
Nexbiome TherapeuticsBGY-16013aAntibodyCandida spp and G. vaginalisIND/CTA ready
Nexbiome TherapeuticsNIN-21013aProtein/PeptideEnterococcus faecium, S. aureus / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
SurvivXSUR-1013cNMEImmune-oncology / SepsisIND/CTA ready
Infex TherapeuticsGON-X3aNMEN. Gonorrhoeae / Resistant Neisseria GonorrhoeaLead opt
Infex TherapeuticsVAP-X4aNMEP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
Disperazol PharmaDisperazol3dNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Disperazol PharmaDisperazol1bNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Osta TherapeuticsOsta 27OtherA. baumannii, P. aeruginosa, M. tuberculosis / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
AUROBAC THERAPEUTICSATX4013aProtein/PeptideGram-negative pathogens / Treatment of HAP/VAP caused by Gram-negative bacteria as 1st line therapy suppressing AMR emergencePre-clinical
AUROBAC THERAPEUTICSATX1014aNMETreatment of early septic shock to prevent progression and improve outcomePre-clinical
NanoRevivStaph-EX3aOtherS. aureus, Group A Streptococci, Group B Streptococci / Skeletal InfectionsPre-clinical
discoveric bio betaNIDB-30023aNMEP. aeruginosa / Cystic fibrosis associated infectionsLead opt
discoveric bio betaNIDB-30013aNMEE. coli, K. pneumoniae / Bloodstream infectionsLead opt
Omnix MedicalOMN713aProtein/PeptideSalmonella spp., S. aureus / Skin and Skin-structure infections (ABSSSI)Pre-clinical
Omnix MedicalOMN513aProtein/PeptideEnterobacter spp., P. aeruginosa, S. aureus / Cystic Fibrosis associated infectionsPre-clinical
Infex TherapeuticsRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase II
Infex TherapeuticsMET-X3dNMEA. baumannii, P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)IND/CTA ready
Infex TherapeuticsRDX-023aNMEGram-negative AMR infectionsLead opt
AdjuTec PharmaAPC2473dNMEE. coli, K. pneumoniae / Complicated urinary tract infections (cUTI)IND/CTA ready
F2GOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractoryPhase III
AdjuTec PharmaAPC1483dNMEK. pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI)Phase I
OLGRAMOL20015aProtein/PeptideP. aeruginosa; Broad-spectrum G+/G- / Cystic fibrosis associated infectionsPre-clinical
Selmodslm 5003aNMEE. coli; Broad-spectrum G+/G- / Complicated urinary tract infections (cUTI)IND/CTA ready
Selmodslm 3003aNMEK. pneumoniae; Broad-spectrum G+/G- / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Selmodslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris / Invasive spergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisaLead opt
Assuré MedicalSol-UTI1bOtherP. aeruginosa, S.aureus / Uncomplicated urinary tract infections (uUTI)Pre-clinical
BioVersysBV1003aNMEA. baumannii / HAP, VAP, BSIPhase II
ANTABIOSBLi (ANT3310)3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) IND/CTA ready
VibioSphenVIKYNG3aOtherA. baumannii, P. aeruginosa, S. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
QureTech BioGmP3aNMEE. faecium, S. aureus / Skin and Skin-structure infections (ABSSSI)Lead opt
QureTech BioMTI3aNMEMycobacterium tuberculosis / TuberculosisLead opt
Omnix MedicalOMN63a/5aProtein/PeptideA. baumannii, P. aeruginosa, E. coli, K. pneumoniae; Enterobacter spp / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase I
Northern AntibioticsNAB8153aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
Northern AntibioticsNAB7393aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
tamrisa2G-DAB3aNMEEnterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI)Lead opt
tamrisaEBL-14633aNMEEnterobacterales/Complicated urinary tract infections (cUTI)Pre-clinical
IMMUNETHEPUNImAb3cAntibodyE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
IMMUNETHEPPNV1aVaccineE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci /Healthcare associated CAPIND/CTA ready
HypharmHY-1331bPhageStaphylococcus aureus/Nasal colonization with MRSAPhase I
Eligo BioscienceEB0041bPhageEscherichia coli; Klebsiella pneumoniae/Bloodstream infectionsPre-clinical
Debiopharm InternationalDebio 14533aNMENeisseria gonorrhoeae / GonorrhoeaIND/CTA ready
Debiopharm InternationalAfabicin3aNMEStaphylococcus spp./ABSSSI (caused by S. aureus), bone and joint infectionsPhase II
CombioxinCAL024aOtherVirulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumoniaPhase II
Centauri TherapeuticsABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPre-clinical
Centauri TherapeuticsABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersysBV2004aNMES. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersysBV5003aNMEA. baumannii, S. aureus, Mycobacterium tuberculosis / Cystic fibrosis associated infectionsLead opt
BioVersysalpibectir (BVL-GSK098)3dNMEM. tuberculosis/TuberculosisPhase II
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMEHospital- and community-acquired bacterial pneumonia (HABP, CABP)Marketed
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMEStaphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP)Marketed
ANTABIOPEi (ANT3273)3cNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
ANTABIOMBLi (ANT2681)3dNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI)IND/CTA ready
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, APPhase III
AktheliaAKT-0113cNMEE. coli, Salmonella spp / Febrile NeutropeniaPre-clinical
< PreviousPage 1/10show allNext >

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline DX

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
MicrobiraMAAP-IRPathogen ID75% of Routine Clinical Isolates
Bacteria 94% correct identification: yeasts 95%		From isolated colony
Infrared spectroscopy
<30 minutes		CE-IVD and/or FDA 510k
MicrobiraMicrobira PrototypeFrom PBS + Isolated colony
Infrared spectroscopy
<4h		Prototype in Lab
MicrobiraMicrobira PrototypeFrom positive blood culture
Infrared spectroscopy
<30 minutes		Prototype in Lab
NosticsDUTIPathogen IDMultiplex bacteria
Urinary Tract infections		From urine
Surface Enhanced Raman Spectroscopy
<30 minutes		Feasibility Phase
MolsidfMicRapid antimicrobial susceptibility testAll
AST		From isolated colony
Proprietary reader
<4h		Feasibility Phase
MolsidPythia UTIAMR Mechanism of Resistance IDAll
From urine
Microplate-reader
<2h		Development Phase
MolsidPythia StaphAMR Mechanism of Resistance IDS. aureus
From isolated colony
Microplate-reader
<2h		Development Phase
< PreviousPage 1/1Next >

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

BEAM Alliance ©2025

Legal notice | Photo credits

Connect with us